| Literature DB >> 30639819 |
Norimichi Hattori1, Yukiko Kawaguchi2, Yohei Sasaki2, Shotaro Shimada2, So Murai2, Maasa Abe2, Yuta Baba2, Megumi Watanuki2, Shun Fujiwara2, Nana Arai2, Nobuyuki Kabasawa2, Hiroyuki Tsukamoto2, Yui Uto2, Kouji Yanagisawa2, Bungo Saito2, Hiroshi Harada2, Tsuyoshi Nakamaki2.
Abstract
After allogeneic stem cell transplantation (alloSCT), several immune checkpoints play an important role in the antileukemic immune response in the bone marrow (BM) microenvironment. However, immune checkpoint expression levels in the BM have not been reported after alloSCT in patients with acute myeloid leukemia (AML). We investigated the clinical impact of immune checkpoint expression in BM samples after alloSCT for AML. Higher expression of T cell immunoreceptor with Ig and ITIM domains (TIGIT) was associated with a decreased incidence of acute graft-versus-host disease (P = .048) and poor overall (P = .046) and progression-free survival (P = 0.024). In addition, higher expression of TIGIT at engraftment after alloSCT was correlated with a decreased number of natural killer cells in BM (P = .019). Monitoring TIGIT expression in the BM could be useful for predicting outcome after alloSCT for AML. Our findings raise the possibility that blockade of TIGIT would improve survival.Entities:
Keywords: Allogeneic stem cell transplantation; DNAM-1; Immune checkpoints; PVR; PVRL1; TIGIT
Mesh：
Substances：
Year: 2019 PMID： 30639819 DOI： 10.1016/j.bbmt.2019.01.013
Source DB: PubMed Journal: Biol Blood Marrow Transplant ISSN： 1083-8791 Impact factor: 5.742